AI Verdict
EPAM has stronger fundamentals based on our AI analysis.
EPRX vs EPAM Fundamental Comparison
| Metric | EPRX | EPAM |
|---|---|---|
| Revenue | N/A | $5.5B |
| Net Income | N/A | $377.7M |
| Net Margin | N/A | 6.9% |
| ROE | N/A | 10.3% |
| ROA | N/A | 7.7% |
| Current Ratio | N/A | 2.59x |
| Debt/Equity | N/A | 0.01x |
| EPS | N/A | $6.72 |
Green = Better metric | Red = Weaker metric
You Might Also Compare
EPRX vs EPAM: Frequently Asked Questions
Is EPRX or EPAM a better buy in 2026?
Based on dual AI fundamental analysis (Claude and ChatGPT), EPAM has stronger fundamentals. EPRX is rated SELL (95% confidence) while EPAM is rated BUY (78% confidence). This is not investment advice.
How does EPRX compare to EPAM fundamentally?
EUPRAXIA PHARMACEUTICALS INC. has ROE of N/A vs EPAM Systems, Inc.'s 10.3%. Net margins are N/A vs 6.9% respectively.
Which stock pays higher dividends, EPRX or EPAM?
EPRX has a dividend yield of N/A or no dividend while EPAM has N/A or no dividend. Check individual stock pages for detailed dividend history and payout ratios.
Should I invest in EPRX or EPAM for long term?
For long-term investing, consider that EPRX has SELL rating with 95% confidence, while EPAM has BUY rating with 78% confidence. Higher confidence indicates more consistent fundamentals from SEC filings. This is not investment advice - always do your own research.
What do the AI models say about EPRX vs EPAM?
Our dual AI system (Claude by Anthropic and ChatGPT by OpenAI) analyzes SEC 10-K and 10-Q filings independently. For EPRX vs EPAM, the AI consensus favors EPAM based on fundamental metrics including revenue growth, profitability, ROE, and balance sheet strength.